NASDAQ · Financial Statements
Ascendis Pharma A/S - Ordinary Share (ASND) Financial Statements
$229.23
NASDAQ: ASND
Market Cap $14.24B
Overview Financials Dividend Ascendis Pharma A/S - Ordinary Share most recently reported annual revenue of $692.0M, net profit of $-219.0M, revenue has compounded at 150.6% a year over the last five years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $8.0M $51.0M $267.0M $364.0M $692.0M Operating Profit $-452.0M $-562.0M $-456.0M $-279.0M $-131.0M Net Profit $-384.0M $-583.0M $-481.0M $-378.0M $-219.0M EPS $-7.00 $-10.40 $-8.55 $-6.53 $-3.62 Op Margin -5808.6% -1097.8% -170.8% -76.7% -18.9%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $1.1B $1.1B $826.0M $1.2B $1.3B Total Liabilities $201.0M $826.0M $971.0M $1.3B $1.5B Cash $446.0M $445.0M $392.0M $560.0M $616.0M Borrowings $210.0M $618.0M $743.0M $857.0M $871.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-418.0M $-496.0M $-467.0M $-306.0M $52.0M Investing Cash Flow $-135.0M $47.0M $284.0M $5.0M $-16.0M Financing Cash Flow $-10.0M $-100.0M $8.0M $11.0M $-28.0M Net Cash Flow $-138.0M $-1.0M $-53.0M $167.0M $123.0M Free Cash Flow $-442.0M $-510.0M $-470.0M $-308.0M $44.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.03 EV / EBITDA 157.50 FCF Yield 2.66% Quick Ratio 2.32 Interest Coverage 0.67 Return 1Y 6.73% Return 3Y 144.88% Return 5Y 36.67%
Screens featuring this stock